Skip Navigation

JNCI Journal of the National Cancer Institute 2008 100(1):1; doi:10.1093/jnci/djm296
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation, Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Early Breast Cancer, HER2 Status, and Adjuvant Anthracyclines

In the treatment of early breast cancer, anthracycline-based adjuvant chemotherapy improves disease-free and overall survival compared with non–anthracycline-based adjuvant chemotherapy. However, it is unclear whether the response depends on the HER2 status of the breast tumors. Gennari et al. (p. 14) performed a pooled analysis of data from eight randomized controlled trials that compared anthracycline-based with non–anthracycline-based adjuvant chemotherapy regimens in early breast cancer treatment. The analysis included 6,564 randomly assigned patients, 5,354 of whom had HER2 status information available. Anthracyclines were superior to non–anthracyclines in terms of disease-free and overall survival . . . [Full Text of this Article]

Systemic Adjuvant Therapy and Contralateral Breast Cancer Risk

Quality of Care for Nursing Home Residents Treated for Cancer

Environmental Influences on Risk for Testicular Cancer in Denmark

DNA Breakpoint Information and Breast Cancer Recurrence

Cannabinoid Treatment and Cancer Cell Invasiveness In Vitro


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
C. Laverdiere, Q. Liu, Y. Yasui, P. C. Nathan, J. G. Gurney, M. Stovall, L. R. Diller, N.-K. Cheung, S. Wolden, L. L. Robison, et al.
Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study
J Natl Cancer Inst, August 19, 2009; 101(16): 1131 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M.S. Bartlett, A. Munro, D. A. Cameron, J. Thomas, R. Prescott, and C. J. Twelves
Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
J. Clin. Oncol., November 1, 2008; 26(31): 5027 - 5035.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. J. Thun, L. M. Hannan, and M. Stefanek
Risky Business: Tools to Improve Risk Communication in a Doctor's Office
J Natl Cancer Inst, June 18, 2008; 100(12): 830 - 831.
[Full Text] [PDF]